Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
Authors:
- Akinori MinatoAMAkinori Minato
- Nobuki FurubayashiNFNobuki Furubayashi
- Yujiro NagataYNYujiro Nagata
- Toshihisa TomodaTTToshihisa Tomoda
- Hiroyuki MasaokaHMHiroyuki Masaoka
- Yoohyun SongYSYoohyun Song
- Yoshifumi HoriYHYoshifumi Hori
- Keijiro KiyoshimaKKKeijiro Kiyoshima
- Takahito NegishiTNTakahito Negishi
- Kentaro KuroiwaKKKentaro Kuroiwa
- Narihito SekiNSNarihito Seki
- Ikko TomisakiITIkko Tomisaki
Open Access
- 3 February 2024
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 31 (2) , 862-871
Abstract
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. Hence, this study aimed to assess the oncological outcomes of patients with SUC treated with EV for metastatic disease. We retrospectively evaluated consecutive patients with advanced lower and upper urinary tract cancer who received EV after platinum-based chemotherapy and immune checkpoint blockade therapy at six institutions. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between patients with pure urothelial carcinoma (PUC) and those with SUC. We identified 44 and 18 patients with PUC and SUC, respectively. Squamous differentiation was the most common subtype element, followed by glandular differentiation and sarcomatoid subtype. Although patients with SUC had a comparable ORR to those with PUC, the duration of response for SUC was short. Patients with SUC had poorer PFS than those with PUC; however, no significant difference was observed in OS. Multivariate analysis revealed that SUC was significantly associated with shorter PFS. Although the response of metastatic SUC to EV was similar to that of PUC, SUC showed faster progression than PUC.Keywords
Funding Information
- JSPS KAKENHI (JP23K15773)
This publication has 29 references indexed in Scilit:
- A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical CystectomyJournal of Urology, 2020
- What Is the Significance of Variant Histology in Urothelial Carcinoma?European Urology Focus, 2020
- Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-AnalysisJournal of Urology, 2020
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology, 2019
- The pathologist's role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detectionMinerva Urology and Nephrology, 2018
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Analysis From the National Cancer Data BaseJournal of Clinical Oncology, 2016
- The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial CarcinomaPLOS ONE, 2015
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009